Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro
Chelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep · 2026
Read Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro by Chelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351131.txt.
Description
A lab-made antibody called iscalimab was meant to calm autoimmunity by blocking a key immune handshake, yet trials in transplantation disappointed. Chelsea Gootjes and colleagues tested a copy of the antibody on T cells in dishes to see whether T cell control was the weak point, in this 2026 PLOS One study.
The antibody bound its targets and completely stopped B cell growth, matching earlier reports. But it barely slowed diabetes-linked T cell clones that attack insulin-making cells, and it did not curb fresh T cell responses either. The authors argue this blind spot may explain the limited clinical benefit seen so far.
Catalog record
| CREATOR | Chelsea Gootjes, Jaap Jan Zwaginga, Tatjana Nikolic, Bart O Roep |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25175 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |